Background: To report the results of the International Infection Control Consortium (INICC) study conducted in Kuwait from November 2013-March 2015.
Methods: A device-associated health care–acquired infection (DA-HAI) prospective surveillance study in 7 adult, pediatric, and neonatal intensive care units (ICUs) using the U.S. Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) definitions and INICC methods.
Results: We followed 3,732 adult and pediatric patients for 21,611 bed days and 671 neonatal patients for 4,515 bed days. In the medical-surgical ICUs, the central line–associated bloodstream infection (CLABSI) rate was 3.5 per 1,000 central line days, the ventilator-associated pneumonia (VAP) rate was 4.0 per 1,000 mechanical ventilator days, and the catheter-associated urinary tract infection (CAUTI) rate was 3.3 per 1,000 urinary catheter days; all of them were lower than INICC rates (CLABSI: 4.9; VAP: 16.5; and CAUTI: 5.3) and higher than NHSN rates (CLABSI: 0.9; VAP: 1.1; and CAUTI: 1.2). Resistance of Staphylococcus aureus to oxacillin was 100%, resistance of Acinetobacter baumannii to imipenem and meropenem was 77.6%, and resistance of Klebsiella pneumoniae to imipenem and meropenem was 29.4%. Extra length of stay was 27.1 days for CLABSI, 22.2 days for VAP, and 19.2 days for CAUTI in adult and pediatric ICUs. Extra crude mortality was 19.9% for CLABSI, 30.9% for VAP, and 11.1% for CAUTI in adult and pediatric ICUs.
Conclusions: DA-HAI rates in our ICUs are higher than the CDC-NSHN rates and lower than the INICC international rates.
Al-Mousa, H.H., Omar, A.A., Rosenthal, V.D., Salama, M.F., Aly, N.Y., El-Dossoky Noweir, M., Rebello, F.M., Narciso, D.M., Sayed, A.F., Kurian, A., George, S.M., Mohamed, A.M., Ramapurath, R.J. and Varghese, S.T. (2016) Device-associated infection rates, bacterial resistance, length of stay, and mortality in Kuwait: International Nosocomial Infection Consortium findings. American Journal of Infection Control. January 5th. .
Thank you to our partners for supporting IVTEAM